Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Neoplasm, Residual × talquetamab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 17 Recurrence 1 Neoplasm, Residual 1 Leukemia, Plasma Cell 1 Infections 1 Immunoglobulin Light-chain Amyloidosis 1 Hematologic Neoplasms 1 Cytokine Release Syndrome 1

Interventions

Cyclophosphamide 7 venetoclax 6 Azacitidine 6 fludarabine 5 Cytarabine 4 Blood Specimen Collection 4 daratumumab 3 blinatumomab 3 Daunorubicin 3 tislelizumab 2 fludarabine phosphate 2 Liquid Biopsy 2 Lenalidomide 2 Idarubicin 2 Gemtuzumab 2 Capecitabine 2 Busulfan 2 trastuzumab deruxtecan 1 thymoglobulin 1 tetrathiomolybdate 1 talquetamab 1 tagraxofusp 1 sugemalimab 1 sacituzumab govitecan 1 relugolix 1 pembrolizumab 1 pegaspargase 1 palbociclib 1 obinutuzumab 1 ivosidenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06993675 2025-08-29

ROTATE

Yale University

Phase 2 Recruiting

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡